The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs by $7.3 billion over six years.
The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback